ArticleAmerican journal of translational research2025
Elevated Serum DcR3, Fas, and NLR Ratio are correlated with the progression of Liver Cirrhosis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the correlation between serum levels of decoy receptor 3 (DcR3), neutrophil-to-lymphocyte ratio (NLR), and Fas with the prognosis of liver cirrhosis, with the aim of providing clinical reference for the evaluation of cirrhosis.
methods123 patients with liver cirrhosis were retrospectively selected as the observation group, and 123 healthy individuals as the control group. Serum DcR3, Fas, and peripheral blood NLR were measured and compared between groups. Differences in these indicators were analyzed among patients with varying cirrhosis types and those with liver cancer. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive value of each indicator for cirrhosis progression to liver cancer.
resultsSerum levels of DcR3, Fas, and peripheral blood NLR were significantly higher in the observation group compared to the control group (P < 0.05). Among cirrhosis subtypes, patients with liver cancer exhibited the highest levels of DcR3, Fas, and NLR, followed by those with decompensated cirrhosis, with the lowest levels observed in patients with compensated cirrhosis (P < 0.05). Additionally, cirrhosis patients showed significantly higher levels of these markers than compensated cirrhosis patients (P < 0.05). Among patients with different grades of cirrhosis, the levels of each indicator were highest in grade C, followed by grade B, and lowest in grade A (P < 0.05). ROC curve analysis showed that DcR3, Fas, and NLR were significant predictors of cirrhosis progression to liver cancer (P < 0.05).
conclusionSerum levels of DcR3, Fas, and peripheral blood NLR increase with the progression of liver cirrhosis, demonstrating significant diagnostic value for assessing the prognosis of cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.